β-hydroxybutyrate Impedes the Progression of Alzheimer's Disease and Atherosclerosis in ApoE-Deficient Mice

Nutrients. 2020 Feb 13;12(2):471. doi: 10.3390/nu12020471.

Abstract

β-hydroxybutyrate (β-OHB) has been shown to exert an anti-inflammatory activity. Apolipoprotein-E (ApoE) is strongly associated with atherosclerosis and Alzheimer's disease (AD). This study aimed to explore the therapeutic effect of β-OHB in the brain and the aorta of high-fat diet (HFD)-fed ApoE-deficient mice. We found in Apo-E deficient mice that β-OHB attenuated lipid deposition in the choroid plexus (ChP) and decreased amyloid plaque in the substantia nigra pars compacta. We also found decreased CD68-positive macroglia infiltration of the ChP in β-OHB-treated ApoE-deficient mice. β-OHB treatment ameliorated IgG extravasation into the hippocampal region of the brain. In vitro study using ChP mice cell line revealed that β-OHB attenuated oxidized low-density lipoprotein-induced ApoE-specific differentially expressed inflammatory ChP genes. Treatment with β-OHB reduced aortic plaque formation without affecting blood lipid profiles and decreased serum production of resistin, a well-established risk factor for both AD and atherosclerosis. Thus, the current study suggests and describes the therapeutic potential of β-OHB for the treatment of AD and atherosclerosis.

Keywords: Alzheimer’s disease; apolipoprotein-E; atherosclerosis; choroid plexus; β-hydroxybutyrate.

MeSH terms

  • 3-Hydroxybutyric Acid / pharmacology*
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / etiology
  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Aorta / drug effects
  • Apolipoproteins E / deficiency
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / etiology
  • Brain / drug effects
  • Diet, High-Fat
  • Disease Models, Animal
  • Disease Progression
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Plaque, Amyloid

Substances

  • Anti-Inflammatory Agents
  • Apolipoproteins E
  • 3-Hydroxybutyric Acid